HealthCap VII, L.P. 4
4 · Aprea Therapeutics, Inc. · Filed Oct 7, 2019
Insider Transaction Report
Form 4
HealthCap VII, L.P.
10% Owner
Transactions
- Conversion
Common Stock
[F1][F2]2019-10-07+1,661,382→ 1,671,941 total(indirect: See footnote) - Conversion
Common Stock
[F1][F2]2019-10-07+427,496→ 2,099,437 total(indirect: See footnote) - Purchase
Common Stock
[F2]2019-10-07$15.00/sh+266,667$4,000,005→ 2,366,104 total(indirect: See footnote) - Conversion
Series B Convertible Preferred Stock
[F1][F2]2019-10-07−1,661,382→ 0 total(indirect: See footnote)→ Common Stock (1,661,382 underlying) - Conversion
Series C Convertible Preferred Stock
[F1][F2]2019-10-07−427,496→ 0 total(indirect: See footnote)→ Common Stock (427,496 underlying)
Footnotes (2)
- [F1]Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.
- [F2]The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.